Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 3, 2010, Pages 207-211

  Horoz, Mehmet ^a   Aslan, Mehmet ^a   Bolukbas, Fusun F ^a   Bolukbas, Cengiz ^a   Nazligul, Yasar ^a   Celik, Hakim ^a   Aksoy, Nurten ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Dipeptidases; Fatty liver; Fibrosis; Liver biopsy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; PROLINE DIPEPTIDASE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; SPECTROPHOTOMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOCATALYSIS; BIOLOGICAL MARKERS; DIPEPTIDASES; ENZYME ASSAYS; ETHANOL; FATTY LIVER; FEMALE; HUMANS; LIPIDS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 77953509144     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20334     Document Type: Article

References (34)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438. (Pubitemid 10057164)
2. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
3. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-845.
4. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19:221-229.
5. Horoz M, Bolukbas C, Bolukbas FF, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005;5:35.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
7. Ernst P. Review article: The role of inflammation in the pathogenesis of gastric cancer. Alim Pharmacol Ther 1999;13:13-18. (Pubitemid 29142255)
8. Zanaboni G, Dyne KM, Rossi A, Monafo V, Cetta G. Prolidase deficiency: Biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica 1994;79:13-18.
9. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997;67:166-175.
10. Brosset B, Myara I, Fabre M, Lemonnier A. Plasma prolidase and prolinase activity in alcoholic liver disease. Clin Chim Acta 1988;175:291-295.
11. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: A possible index of collagen catabolism in chronic liver disease. Clin Chem 1984;30:211-215. (Pubitemid 14190267)
12. Kayadibi H, Gültepe M, Yasar B, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: A surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2008 Nov 7. DOI: 10.1007/s10620-008-0535-0.
13. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: Application to imminodipeptiduria. Clin Chim Acta 1982;125:193-205.
14. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem 1952;199:91-95.
15. Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997;265:21-31.
16. James CH, Lindor KD. Outcome of patients admitted with complications after outpatient liver biopsies. Ann Intern Med 1993;118:96-98.
17. Rousselet MC, Michalak S, Dupré F, et al. Hepatitis Network 49: Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-264.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
19. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-1075.
20. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481.
21. Parés A, Deulofeu R, Giménez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996;24:1399-1403.
22. Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003;18:253-257.
23. Weigand K, Zaugg PY, Frei A, Zimmermann A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835-838. (Pubitemid 14007650)
24. Fontana RJ, Goodman ZD, Dienstag JL, et al. HALT-C Trial Group: Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-798.
25. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007;25:207-218.
26. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-434.
27. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006;55:403-408.
28. Park GJ, Katelaris PH, Jones DB, et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005;22:395-403.
29. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-1713.
30. Yaron A, Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol 1993;28:31-81. (Pubitemid 23065603)
31. Aslan M, Nazligul Y, Horoz M, et al. Serum prolidase activity and oxidative status in Helicobacter pylori infection. Clin Biochem 2007;40:37-40. (Pubitemid 46014156)
32. Cakmak A, Zeyrek D, Atas A, Celik H, Aksoy N, Erel O. Serum prolidase activity and oxidative status in patients with bronchial asthma. J Clin Lab Anal 2009;23:132-138.
33. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-1109.
34. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.